ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Pennsylvania » Hematology Oncology

Top Hematology Oncology Prescribers in Pennsylvania

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
DUILIO VALDIVIA MD

Hematology Oncology

12,282

$610K

240
198 are 65+

12%
patients receiving schedule two controlled substances

Avg: 14%

25%
patients receiving schedule three controlled substances

Avg: 3%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 18%

$50
Average prescription price

Avg: $491

JOSEPH GALL M.D.

Hematology Oncology

11,416

$555K

299
291 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

10%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 18%

$49
Average prescription price

Avg: $491

RICARDO CARTER MD

Hematology Oncology

3,113

$746K

215
174 are 65+

6%
patients receiving schedule two controlled substances

Avg: 14%

12%
patients receiving schedule three controlled substances

Avg: 3%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 18%

$240
Average prescription price

Avg: $491

HOWARD KIRTLAND M.D.

Hematology Oncology

2,893

$668K

284
242 are 65+

18%
patients receiving schedule two controlled substances

Avg: 14%

5%
patients receiving schedule three controlled substances

Avg: 3%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$231
Average prescription price

Avg: $491

MARK KEATING M.D.

Hematology Oncology

2,335

$1.19M

285
252 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

16%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 18%

$508
Average prescription price

Avg: $491

RENE RUBIN MD

Hematology Oncology

2,194

$860K

273
192 are 65+

20%
patients receiving schedule two controlled substances

Avg: 14%

5%
patients receiving schedule three controlled substances

Avg: 3%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 18%

$392
Average prescription price

Avg: $491

DAVID GREENWALD MD

Hematology Oncology

2,133

$1.23M

348
301 are 65+

15%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 18%

$575
Average prescription price

Avg: $491

SIGURDUR PETURSSON MD

Hematology Oncology

2,119

$539K

268
224 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

10%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$255
Average prescription price

Avg: $491

JAGJIT TANDON MD

Hematology Oncology

2,016

$496K

136
101 are 65+

0%
patients receiving schedule two controlled substances

Avg: 14%

21%
patients receiving schedule three controlled substances

Avg: 3%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 18%

$246
Average prescription price

Avg: $491

KEVIN KANE M.D.

Hematology Oncology

2,008

$980K

234
199 are 65+

20%
patients receiving schedule two controlled substances

Avg: 14%

21%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$488
Average prescription price

Avg: $491

STEPHEN SHORE M.D.

Hematology Oncology

2,001

$289K

167
149 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 18%

$144
Average prescription price

Avg: $491

WILLIAM RYAN MD

Hematology Oncology

1,990

$934K

273
233 are 65+

17%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 18%

$469
Average prescription price

Avg: $491

MARTIN EARLE M.D.

Hematology Oncology

1,945

$857K

279
250 are 65+

21%
patients receiving schedule two controlled substances

Avg: 14%

12%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

10%
prescriptions for brand name drugs

Avg: 18%

$440
Average prescription price

Avg: $491

BRUCE SAIDMAN MD

Hematology Oncology

1,898

$1.27M

255
226 are 65+

10%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 18%

$668
Average prescription price

Avg: $491

TERRY EVANS M.D.

Hematology Oncology

1,798

$694K

260
223 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

8%
patients receiving schedule three controlled substances

Avg: 3%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$386
Average prescription price

Avg: $491

EDWARD WYSHOCK MD, FACP

Hematology Oncology

1,681

$471K

207
166 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

12%
patients receiving schedule three controlled substances

Avg: 3%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 18%

$280
Average prescription price

Avg: $491

JAMES LICHTER M.D.

Hematology Oncology

1,642

$844K

230
194 are 65+

7%
patients receiving schedule two controlled substances

Avg: 14%

6%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 18%

$514
Average prescription price

Avg: $491

ANASTASIOS RAPTIS M.D.

Hematology Oncology

1,585

$902K

123
82 are 65+

24%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 18%

$569
Average prescription price

Avg: $491

SAJID PERACHA M.D.

Hematology Oncology

1,545

$1.04M

213
167 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 3%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 18%

$673
Average prescription price

Avg: $491

DAVID MINTZER MD

Hematology Oncology

1,438

$965K

268
222 are 65+

20%
patients receiving schedule two controlled substances

Avg: 14%

4%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 18%

$671
Average prescription price

Avg: $491

MOHAMMED ISLAM MD

Hematology Oncology

1,434

$953K

199
140 are 65+

15%
patients receiving schedule two controlled substances

Avg: 14%

9%
patients receiving schedule three controlled substances

Avg: 3%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

24%
prescriptions for brand name drugs

Avg: 18%

$664
Average prescription price

Avg: $491

DAVID FRIEDLAND M.D.

Hematology Oncology

1,433

$1.36M

192
166 are 65+

24%
patients receiving schedule two controlled substances

Avg: 14%

14%
patients receiving schedule three controlled substances

Avg: 3%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 18%

$950
Average prescription price

Avg: $491

CHARLES SRODES MD

Hematology Oncology

1,411

$302K

110
96 are 65+

18%
patients receiving schedule two controlled substances

Avg: 14%

0%
patients receiving schedule three controlled substances

Avg: 3%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

24%
prescriptions for brand name drugs

Avg: 18%

$214
Average prescription price

Avg: $491

ROY WILLIAMS M.D.

Hematology Oncology

1,409

$568K

173
138 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

15%
patients receiving schedule three controlled substances

Avg: 3%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 18%

$403
Average prescription price

Avg: $491

SUBHASH PROOTHI MD

Hematology Oncology

1,392

$894K

254
223 are 65+

10%
patients receiving schedule two controlled substances

Avg: 14%

4%
patients receiving schedule three controlled substances

Avg: 3%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$642
Average prescription price

Avg: $491

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank